Research milestones and news from ORGANOPlus.
ORGANOPlus established its first European entity in Copenhagen
By establishing its first European entity in Copenhagen, South Korean ORGANOPlus embeds its validation platform within Medicon Valley’s strong ecosystem. And it’s doing so with assistance from Copenhagen…
ORGANOPlus Reports First-Ever Preclinical Anti-Cancer Data for Bifidobacteria-Derived Candidate OP820
• ORGANOPlus presented first-ever preclinical anti-cancer data for its Bifidobacteria-derived candidate OP820 at ACLAB 15 in Taipei. • The company is preparing to establish a Denmark subsidiary to…
BIO-Europe 2025: ORGANOPlus Strengthens Global Partnerships in Vienna
ORGANOPlus participated in BIO-Europe 2025 held in Vienna, Austria,meeting with over 30 leading European biopharma companies and exploring collaborationswith key research institutes in the Czech Republic and Germany…
Suwon Urban Foundation Hosts ‘Suwon Global Demo Day’ in Singapore, Featuring ORGANOPlus and Six Other Startups
The Suwon Urban Foundation held the ‘Suwon Global Demo Day’ on October 31 at Singapore’s Centennial Tower, where ORGANOPlus and six other promising Suwon-based startups were selected to…
CEO Jaeyoung Shin Leads ORGANOPlus to Redefine Drug Development with Human Organoid Chip Platforms
ORGANOPlus, founded by CEO Jaeyoung Shin, is pioneering organoid chip platforms that replicate complex human microenvironments with unmatched precision. Its flagship technologies—VILLIORGAN™ (gut organoid chip) and CANORGAN™ (tumor…
Harvard Medical School and ORGANOPlus Join Forces to Advance Next-Generation IBD Organoid Chip Models
ORGANOPlus signed an MOU with Harvard Medical School to co-develop intestinal muscle–integrated IBD organoid chip models. The partnership combines Harvard’s bio-printed muscle expertise with ORGANOPlus’s VILLIORGAN™ platform to…
